Elizaveta Samorodova

Dr. Elizaveta Samorodova

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2021 in Molbank
Verified
Journal Article
Open access
PDF file
Anastasia KovrizhinaAnastasia Kovrizhina
Anastasia Kovrizhina
ESElizaveta Samorodova
Elizaveta Samorodova
Andrei KhlebnikovAndrei Khlebnikov
Andrei Khlebnikov
11H-Indeno[1,2-b]quinoxaline derivatives present an important type of nitrogen-containing heterocyclic compound that are useful intermediate products in organic synthesis and have potential pharmaceutical applications. A new 11H-indeno[1,2-b]quinoxalin-11-one-2-(4-ethylbenzylidene)hydrazone (compound 3) was synthesized. Compound 3 is the first example of an azine derivative based on the 11H-indeno[1,2-b]quinoxaline system. The Z,E-isomerism of compound 3 was investigated by DFT calculations. Bioavailability was evaluated in silico using ADME predictions. According to the ADME results, compound 3 is potentially highly bioavailable and has potential to be used for the treatment of neuroinflammation and ischemia–reperfusion injury.

29 June 2023 in Ophthalmology in Russia
Verified
Journal Article
Open access
PDF file
IMI. B. Medvedev
I. B. Medvedev
ESElizaveta Samorodova
Elizaveta Samorodova
SSS. V. Svetlichnaya
S. V. Svetlichnaya
LBL. V. Batalina
L. V. Batalina
NDN. N. Dergacheva
N. N. Dergacheva
Uveitis is a term that combines an extensive group of diseases, which are based on inflammation of the choroid of the eyeball. A special place is given to non-infectious uveitis. This group of diseases has an autoimmune origin and the largest proportion of the incidence falls on them. The largest share of morbidity is from this group of uveitis. Despite the successes in modern approaches to the treatment of uveitis, the issue of timely diagnosis and treatment of diseases of the vascular eye membrane does not lose its relevance. The social significance of this pathology is determined by the growing rate of visual acuity decline, the development of complications and early disability. Many studies have revealed a relationship between the untimely late start of treatment and the likelihood of vision loss leading to a deterioration in the quality of life. The therapy of non-infectious uveitis is based on the suppression of the local immune response. Depending on the activity of the inflammatory process, it may include local treatment (instillation of corticosteroids, nonsteroidal anti-inflammatory drugs and mydriatics) and systemic immunosuppression using corticosteroids, alkylating agents (cyclophosphamide, chlorambucil), antimetabolites (azathioprine, methotrexate, mycophenolate mofetil), T-cell inhibitors (cyclosporine and tacrolimus). According to the experience of clinicians, the therapeutic efficacy of steroids even in high doses in treatment of the chronic uveitis provides only partial remission and is associated with the development of serious side effects. Positive results were found when using a combination of steroids with cytostatics, however, with their prolonged use, it is possible to manifest properties such as hepatotoxicity and nephrotoxicity, mutagenicity, carcinogenicity, sterilization, as well as bone marrow suppression, and, as a consequence, the occurrence of severe thrombocytopenic bleeding and granulocytopenic infections. In the case of intermediate, posterior and severe and moderate panuveitis that does not respond to immunosuppressive therapy with methotrexate and cyclosporine A, patients are transferred to therapy with genetically engineered biological drugs (GIBP). The drugs of biological therapy include selective regulators of cytokine levels. The mechanism of their action is based on the selective cytokines’ binding using monoclonal antibodies or soluble cytokine receptors. This article is devoted to evaluating the effectiveness of biological therapy as the drugs of choice.

6 January 2026 in Molbank
Verified
Journal Article
Open access
PDF file
ESElizaveta Samorodova
Elizaveta Samorodova
Anastasia KovrizhinaAnastasia Kovrizhina
Anastasia Kovrizhina
Andrei KhlebnikovAndrei Khlebnikov
Andrei Khlebnikov
A novel unsymmetrical azine, 6-((2-oxoindolin-3-ylidene)hydrazineylidene)indolo[2,1-b]quinazolin-12(6H)-one, was synthesized through a condensation reaction between tryptanthrin-6-hydrazone and isatin in chloroform under reflux conditions. Structural characterization revealed the compound exists as a mixture of geometric isomers with one predominant form. Density functional theory (DFT) calculations identified the E,E configuration as the most stable isomer. The isomerization barriers for both C=N bonds were calculated at approximately 18.5 kcal/mol via nitrogen inversion. Given the established biological activities of tryptanthrin and isatin derivatives, this hybrid azine represents a promising lead compound for developing bifunctional drug candidates.

8 July 2026 in Ophthalmology in Russia
Verified
Journal Article
Open access
PDF file
IMI. B. Medvedev
I. B. Medvedev
NBN. S. Bashmakova
N. S. Bashmakova
NDN. N. Dergacheva
N. N. Dergacheva
NEN. S. Egorova
N. S. Egorova
ESElizaveta Samorodova
Elizaveta Samorodova
AMA. I. Medvedeva
A. I. Medvedeva
Endocrine ophthalmopathy (EO) is one of the most common causes of exophthalmos in adults, as well as optic neuropathy resulting from orbital compartment syndrome. Complications such as persistent vision loss due to pathology of the anterior ocular surface and optic nerve involvement remain high. After compensation for the acute stage of the disease, cosmetic dissatisfaction becomes a primary concern due to significant changes in the periorbital tissues. Current diagnostics and the correct choice of treatment strategy based on the stage and activity of the pathological process are key factors in achieving a positive outcome, both in terms of clinical symptoms and aesthetic defects, particularly blepharochalasis and eyelid malposition. Various treatment methods exist, divided into medical and surgical. Each method has its own indications and contraindications, as well as side effects, which should be considered when choosing a strategy. The latter is especially important when selecting systemic drug therapy. In most cases, surgical treatment requires preliminary complete compensation of the thyroid gland’s hormonal and somatic status. Collaborative management with an endocrinologist is crucial. As noted above, the first step in treating EOP is drug therapy, which involves the use of glucocorticosteroidsin varying dosages, depending on the patient’s initial status and the endocrinologist’s recommendations. Further management is determined based on individual indications and includes various types of surgical treatment, among other options. A key aspect of the surgical approach is a properly developed step-by-step plan for the procedures. Each subsequent step should be a logical continuation of the previous stage of treatment.